An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation.
Latest Information Update: 09 Nov 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 04 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 04 Feb 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 04 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.